Skip to main content

Table 4 Factors associated with virological success

From: Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

  Univariate model   Multivariate model  
Hazard Ratio (95% confidence interval) p-value Hazard Ratio (95% confidence interval) p-value
Region   0.07   < 0.01
 Eastern Europe 1   1  
 Western/Southern Europe 0.99(0.77–1.27)   1.03 (0.75–1.41)  
 Latin America 1.29(0.97–1.73)   1.42 (1.04–1.94)  
Age, years   0.59   0.87
 30 vs 20 1.13(084–1.52)   1.12 (0.83–1.51)  
 40 vs 20 1.24(0.76–2.02)   1.22 (0.74–2.01)  
 50 vs 20 1.26(0.80–2.00)   1.28 (0.80–2.06)  
Male 1.01(0.81–1.27) 0.91 0.93 (0.73–1.18) 0.53
Disseminated TB 0.90(0.73–1.12) 0.34 0.86 (0.69–1.07) 0.17
IDU 1.07(0.85–1.34) 0.58 1.16 (0.87–1.55) 0.30
TB susceptibility   0.79   0.84
 No MDR vs MDR 1.07(0.65–1.75)   1.05(0.62–1.78)  
 No Resistance test vs MDR 1.04(0.63–1.72)   0.98(0.58–1.66)  
Rifamicin 1.25(0.79–1.97) 0.33   
Efavirenz 1.05(0.84–1.30) 0.68 0.97(0.76–1.22) 0.77
ART naïve 1.11(0.90–1.37) 0.33 1.09(0.86–1.39) 0.44
CD4+ at TB diagnosis (cells/mm3)   0.48   0.41
 100 vs 50 0.99(0.90–1.08)   0.99(0.90–1.10)  
 200 vs 50 0.96(0.79–1.16)   0.98(0.79–1.20)  
 350 vs 50 0.91(0.73–1.14)   0.92(0.73–1.17)  
  1. Note: Only 453 patients in care at 12 months were included in this model. Patients without HIV-RNA information were excluded, n = 220
  2. IDU Injection Drug User, MDR-TB Multi-drug resistant tuberculosis